Table 5.
The population coverage calculation for peptides with predicted HLA binding.
Peptide | HLA allele | World population coverage |
---|---|---|
Selected SARS-CoV-2 peptides against 145 HLAs with known global allele frequency | ||
ESGLKTIL | HLA-B*08:01 | 10.55% |
EVLLAPLL | HLA-B*51:07 | 0.12% |
NVAITRAK | HLA-A*34:02 | 0.5% |
RYPANSIV | HLA-A*24:02 | 21.38% |
RYPANSIV | HLA-A*24:03 | 0.49% |
RYPANSIV | HLA-A*24:07 | 1.04% |
RYPANSIV | HLA-C*14:02 | 3.04% |
RYPANSIV | HLA-C*14:03 | 0.87% |
RRSFYVYA | HLA-B*27:02 | 1.58% |
RRSFYVYA | HLA-B*27:03 | 0.24% |
RRSFYVYA | HLA-B*27:04 | 0.79% |
RRSFYVYA | HLA-B*27:05 | 4.78% |
RFNVAITR | HLA-A*33:03 | 4.78% |
RFNVAITR | HLA-A*74:01 | 2.18% |
RYPANSIV | HLA-A*24:02, HLA-A*24:03, HLA-A*24:07, HLA-C*14:02, and HLA-C*14:03 | 25.74% |
RRSFYVYA | HLA-B*27:02, HLA-B*27:03, HLA-B*27:04, and HLA-B*27:05 | 7.33% |
RFNVAITR | HLA-A*33:03 and HLA-A*74:01 | 6.91% |
Selected SARS-CoV-2 peptides against the experimentally confirmed HLAs of equivalent IEDB epitopes | ||
RRSFYVYA | HLA-B*27:05 | 5.36% |
NVAITRAK | HLA-A*11:01 | 15.53% |
RFNVAITR | HLA-A*31:01 | 5.36% |
All peptides against all predicted HLAs | ||
All peptides | all predicted HLAs | 57.41% |